A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

• Status: Completed
• Trial end date: 2018-12-11
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Linrodostat; Nivolumab

Criteria

Inclusion Criteria:

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

• Participants must have histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per Response Evaluation Criteria In Solid Tumors (RECIST v1.1)

• Participants must have received, and then progressed or been intolerant to standard treatment regimen in the advanced or metastatic setting

• Eastern Cooperative Oncology Group performance status of ≤ 1

Exclusion Criteria:

• Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease are excluded

• History of congenital or autoimmune hemolytic disorders

• History or presence of hypersensitivity or idiosyncratic reaction to methylene blue

Other protocol defined inclusion/exclusion criteria could apply